These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 27329552)

  • 1. Improved survival in patients with severe tuberculosis after exposure to fluoroquinolones.
    Chiang SR; Shieh JM; Chen CH; Hsing SC; Wen SF; Wang JJ; Cheng KC; Chuang YC
    Infect Dis (Lond); 2016; 48(11-12):789-95. PubMed ID: 27329552
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Outcomes of pulmonary MDR-TB: impacts of fluoroquinolone resistance and linezolid treatment.
    Jeong BH; Jeon K; Park HY; Kwon OJ; Lee KS; Kim HK; Choi YS; Kim J; Huh HJ; Lee NY; Koh WJ
    J Antimicrob Chemother; 2015 Nov; 70(11):3127-33. PubMed ID: 26203184
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of Fluoroquinolone Exposure Prior to Tuberculosis Diagnosis on Clinical Outcomes in Immunocompromised Patients.
    Lee JY; Lee HJ; Kim YK; Yu S; Jung J; Chong YP; Lee SO; Choi SH; Shim TS; Kim YS; Woo JH; Kim SH
    Antimicrob Agents Chemother; 2016 Jul; 60(7):4005-12. PubMed ID: 27090178
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Empirical use of fluoroquinolones improves the survival of critically ill patients with tuberculosis mimicking severe pneumonia.
    Tseng YT; Chuang YC; Shu CC; Hung CC; Hsu CF; Wang JY
    Crit Care; 2012 Oct; 16(5):R207. PubMed ID: 23098258
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical Impact of Discordant Prescribing of Fluoroquinolones and Alternative Treatments in Escherichia coli Pyelonephritis.
    Hong MT; Seifert CF
    J Pharm Pract; 2016 Oct; 29(5):467-71. PubMed ID: 25660586
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High variability among Emergency Departments in 3rd-generation cephalosporins and fluoroquinolones use for community-acquired pneumonia.
    Batard E; Lecadet N; Goffinet N; Hardouin JB; ; Lepelletier D; Potel G; Montassier E
    Infection; 2015 Dec; 43(6):681-9. PubMed ID: 25998004
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Community-acquired pneumonia: impact of empirical antibiotic therapy without respiratory fluoroquinolones nor third-generation cephalosporins.
    Pradelli J; Risso K; de Salvador FG; Cua E; Ruimy R; Roger PM
    Eur J Clin Microbiol Infect Dis; 2015 Mar; 34(3):511-8. PubMed ID: 25273975
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Does radiographic evidence of prior pulmonary tubercular infection influence the choice of empiric antibiotics for community-acquired pneumonia in a tuberculosis-endemic area?
    Jeng YY; Lin YT; Huang LJ; Chen TL; Wang FD; Fung CP; Liu CY
    J Microbiol Immunol Infect; 2010 Oct; 43(5):386-94. PubMed ID: 21075705
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association between recent use of fluoroquinolones and rhegmatogenous retinal detachment: a population-based cohort study.
    Kuo SC; Chen YT; Lee YT; Fan NW; Chen SJ; Li SY; Liu CJ; Chen TL; Chen TJ; Fung CP
    Clin Infect Dis; 2014 Jan; 58(2):197-203. PubMed ID: 24170197
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analyses of fluoroquinolones and Clostridium difficile-associated diarrhoea in tuberculosis patients.
    Chang KC; Leung CC; Yew WW; Lam FM; Ho PL; Chau CH; Cheng VC; Yuen KY
    Int J Tuberc Lung Dis; 2009 Mar; 13(3):341-6. PubMed ID: 19275794
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Is the delay in diagnosis of pulmonary tuberculosis related to exposure to fluoroquinolones or any antibiotic?
    Wang M; Fitzgerald JM; Richardson K; Marra CA; Cook VJ; Hajek J; Elwood RK; Bowie WR; Marra F
    Int J Tuberc Lung Dis; 2011 Aug; 15(8):1062-8. PubMed ID: 21740669
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The effect of fluoroquinolone use in the respiratory intensive care unit on the development of hospital-acquired MRSA infection and its prognosis].
    Dirican N; Oz AT; Pullukçu H; Aydemir S; Bacakoğlu F
    Mikrobiyol Bul; 2014 Jan; 48(1):28-39. PubMed ID: 24506713
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical Benefit of Appropriate Empirical Fluoroquinolone Therapy for Adults with Community-Onset Bacteremia in Comparison with Third-Generation-Cephalosporin Therapy.
    Lee CC; Wang JL; Lee CH; Hsieh CC; Hung YP; Hong MY; Tang HJ; Ko WC
    Antimicrob Agents Chemother; 2017 Feb; 61(2):. PubMed ID: 27855072
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Initial antibiotic selection and patient outcomes: observations from the National Pneumonia Project.
    Bratzler DW; Ma A; Nsa W
    Clin Infect Dis; 2008 Dec; 47 Suppl 3():S193-201. PubMed ID: 18986289
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Protecting the tuberculosis drug pipeline: stating the case for the rational use of fluoroquinolones.
    Migliori GB; Langendam MW; D'Ambrosio L; Centis R; Blasi F; Huitric E; Manissero D; van der Werf MJ
    Eur Respir J; 2012 Oct; 40(4):814-22. PubMed ID: 22653774
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prediction of Fluoroquinolone Resistance in Gram-Negative Bacteria Causing Bloodstream Infections.
    Dan S; Shah A; Justo JA; Bookstaver PB; Kohn J; Albrecht H; Al-Hasan MN
    Antimicrob Agents Chemother; 2016 Apr; 60(4):2265-72. PubMed ID: 26833166
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical impact of using fluoroquinolone with low antimycobacterial activity on treatment delay in tuberculosis: Hospital-based and population-based cohort study.
    Lee MR; Lee CH; Wang JY; Lee SW; Ko JC; Lee LN
    J Formos Med Assoc; 2020 Jan; 119(1 Pt 2):367-376. PubMed ID: 31262613
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk of severe dysglycemia among diabetic patients receiving levofloxacin, ciprofloxacin, or moxifloxacin in Taiwan.
    Chou HW; Wang JL; Chang CH; Lee JJ; Shau WY; Lai MS
    Clin Infect Dis; 2013 Oct; 57(7):971-80. PubMed ID: 23948133
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative-Effectiveness of Oral Beta-Lactams and Fluoroquinolones for Stepdown Therapy in Patients with Enterobacterales Bloodstream Infections: A Retrospective Cohort Study.
    Bjork L; Hopkins T; Yang L; Teng C; Jones X; Cadena J; Walter E; Frei CR
    Int J Med Sci; 2023; 20(4):437-443. PubMed ID: 37057217
    [No Abstract]   [Full Text] [Related]  

  • 20. Factors associated with death during tuberculosis treatment of patients co-infected with HIV at the Yaoundé Central Hospital, Cameroon: an 8-year hospital-based retrospective cohort study (2006-2013).
    Agbor AA; Bigna JJ; Billong SC; Tejiokem MC; Ekali GL; Plottel CS; Noubiap JJ; Abessolo H; Toby R; Koulla-Shiro S
    PLoS One; 2014; 9(12):e115211. PubMed ID: 25506830
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.